Innate Pharma (IPHYF) Common Equity (2017 - 2019)

Innate Pharma's Common Equity history spans 3 years, with the latest figure at $240.7 million for Q4 2019.

  • For Q4 2019, Common Equity rose 26.07% year-over-year to $240.7 million; the TTM value through Dec 2019 reached $240.7 million, up 26.07%, while the annual FY2019 figure was $240.7 million, 26.07% up from the prior year.
  • Common Equity reached $240.7 million in Q4 2019 per IPHYF's latest filing, up from $190.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $240.7 million in Q4 2019 to a low of $101.2 million in Q4 2017.
  • Average Common Equity over 3 years is $177.6 million, with a median of $190.9 million recorded in 2018.
  • Peak YoY movement for Common Equity: soared 88.61% in 2018, then increased 26.07% in 2019.
  • A 3-year view of Common Equity shows it stood at $101.2 million in 2017, then surged by 88.61% to $190.9 million in 2018, then rose by 26.07% to $240.7 million in 2019.
  • Per Business Quant, the three most recent readings for IPHYF's Common Equity are $240.7 million (Q4 2019), $190.9 million (Q4 2018), and $101.2 million (Q4 2017).